Discovery of orally active indirubin-3′-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia

Pyeonghwa Jeong(Gwangju Institute of Science and Technology), Yoon-Gyoon Kim(Gwangju Institute of Science and Technology), Jungil Choi(Korea Institute of Toxicology), Yeongyu Moon(Korea Institute of Toxicology), So‐Deok Lee(Gwangju Institute of Science and Technology), Sun‐Young Han(University of Colorado Health), Hyun Woo Park(Yonsei University), Jiheon Kim(Seoul National University), Jeong‐Doo Heo(Korea Institute of Toxicology), Ji Eun Shin(Yonsei University), Yong‐Chul Kim(Gwangju Institute of Science and Technology), Jung-Eun Lee(Gwangju Institute of Science and Technology), Jiyeon Park(Gwangju Institute of Science and Technology), Na Yoon Kim(Dankook University), Je‐Heon Lee(Gwangju Institute of Science and Technology), Hyo‐Jeong Lee(Kyung Hee University)
European Journal of Medicinal Chemistry
March 6, 2020
Cited by 29


Related Papers